

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Complete if Known</b>	
				Application Number	10/587,052
				Filing Date	April 9, 2007
				First Named Inventor	Paul A. Bunn Jr.
				Art Unit	1642
				Examiner Name	Sean E. Aeder
Sheet	1	of	1	Attorney Docket Number	5941-65-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2010/0196366	08/05/10	Bunn et al.	
	2	12/670053		Witta et al. (01-21-2010)	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5 (if known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	3	WO 2004/071572	08/26/04	Agus et al.		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. <sup>1</sup>	
	4	Bruzzese et al. "Synergistic antitumor effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in combination with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in squamous-cell carcinoma of the head and neck derived cell lines" Proc. Amer. Assoc. Cancer Res., Vol. 45, 2004, abstract #5625
	5	Jones, et al., "E-cadherin relates to EGFR expression and lymph node metastasis in primary breast carcinoma," British Journal of Cancer, 1996, vol. 74, pages 1237-1241
	6	Shrader et al., "Molecular correlates gefitinib responsiveness in human bladder cancer cells," Molecular Cancer Therapeutics, 2007, vol. 6, pages 277-285
	7	Thomson et al., "Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition," Cancer Research, 2005, vol. 65, pages 9455-9462
	8	International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US08/70930, mailed February 4, 2010 (Attorney's Ref. No. 5941-65-PUS-CIP-PCT)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.